Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefurulimab PFS vs Autoinjector in Healthy Volunteers
NCT06208488Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gefurulimab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area under the serum concentration-time curve from time zero to the last measurable concentration, Area under the serum concentration-time curve from time zero to time infinity and 1 more. Started Nov 2023; status: completed.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06208488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208488.